Prevalence of primary versus reactivated Epstein-Barr virus infection in patients with VCA IgG-, VCA IgM- and EBNA-1-antibodies and suspected infectious mononucleosis
- PMID: 17336144
- DOI: 10.1016/j.jcv.2007.01.006
Prevalence of primary versus reactivated Epstein-Barr virus infection in patients with VCA IgG-, VCA IgM- and EBNA-1-antibodies and suspected infectious mononucleosis
Abstract
Background: In Epstein-Barr virus (EBV) infection, IgG- and IgM-antibodies to viral capsid antigen (VCA) and IgG-antibodies to Epstein-Barr nuclear antigen 1 (EBNA-1) can occur simultaneously both in late primary infection and during subclinical viral reactivation in immunocompetent persons, and the differential diagnosis is of importance.
Objectives: To study the prevalence of primary infection and serological reactivation in patients with suspected primary EBV infection and with all three parameters present.
Study design: Fifty serum samples from 43 consecutive patients referred for suspected infectious mononucleosis and positive for VCA IgG-, VCA IgM- and EBNA-1-antibodies by EIA, were tested for IgG-antibody avidity with an EBV IgG immunoblot. Sera were also tested for heterophile antibodies (HA). To verify the presence of IgM-antibodies an EBV IgM immunoblot was performed when high-avidity IgG-antibodies were found.
Results and conclusions: Of 43 patients with suspected primary EBV infection and VCA IgG-, VCA IgM- and EBNA-1-antibodies present, only 18 patients (42%) had a late primary infection. Twenty-one patients (49%) had high-avidity IgG-antibodies, indicating an IgM response due to reactivation, thus suggesting other causes for their symptoms. In 10 of these 21 patients the presence of IgM-antibodies was confirmed by immunoblot, indicating reactivation as a cause of IgM-antibodies in at least 23% of the 43 patients studied. Of 18 patients with primary infection, HA were detected in 16 (94%) of 17 patients tested. Only one (5%) of the patients with high-avidity antibodies had HA. Absence of HA in patients with this serological pattern is therefore a good indicator of reactivation, and conversely, the presence of HA is a good indicator of primary infection. In HA negative patients, avidity testing could be used for differential diagnosis.
Similar articles
-
Measurement of EBV-IgG anti-VCA avidity aids the early and reliable diagnosis of primary EBV infection.J Med Virol. 2003 Aug;70(4):617-23. doi: 10.1002/jmv.10439. J Med Virol. 2003. PMID: 12794726
-
Evaluation the Architect EBV VCA IgM, VCA IgG, and EBNA-1 IgG chemiluminescent immunoassays to assess EBV serostatus prior transplantation.J Med Virol. 2017 Nov;89(11):2003-2010. doi: 10.1002/jmv.24889. Epub 2017 Aug 1. J Med Virol. 2017. PMID: 28661055
-
Seroepidemiology of EBV and interpretation of the "isolated VCA IgG" pattern.J Med Virol. 2009 Feb;81(2):325-31. doi: 10.1002/jmv.21373. J Med Virol. 2009. PMID: 19107979
-
Serological diagnosis of Epstein-Barr virus infection: Problems and solutions.World J Virol. 2012 Feb 12;1(1):31-43. doi: 10.5501/wjv.v1.i1.31. World J Virol. 2012. PMID: 24175209 Free PMC article. Review.
-
Serological Evidence for the Association Between Epstein-Barr Virus Infection and Sjögren's Syndrome.Front Immunol. 2020 Oct 30;11:590444. doi: 10.3389/fimmu.2020.590444. eCollection 2020. Front Immunol. 2020. PMID: 33193425 Free PMC article.
Cited by
-
Progress and problems in understanding and managing primary Epstein-Barr virus infections.Clin Microbiol Rev. 2011 Jan;24(1):193-209. doi: 10.1128/CMR.00044-10. Clin Microbiol Rev. 2011. PMID: 21233512 Free PMC article. Review.
-
Persistence of EBV antigen-specific CD8 T cell clonotypes during homeostatic immune reconstitution in cancer patients.PLoS One. 2013 Oct 25;8(10):e78686. doi: 10.1371/journal.pone.0078686. eCollection 2013. PLoS One. 2013. PMID: 24205294 Free PMC article. Clinical Trial.
-
Evaluation of the Architect Epstein-Barr Virus (EBV) viral capsid antigen (VCA) IgG, VCA IgM, and EBV nuclear antigen 1 IgG chemiluminescent immunoassays for detection of EBV antibodies and categorization of EBV infection status using immunofluorescence assays as the reference method.Clin Vaccine Immunol. 2014 May;21(5):684-8. doi: 10.1128/CVI.00104-14. Epub 2014 Mar 12. Clin Vaccine Immunol. 2014. PMID: 24623623 Free PMC article.
-
Performance of two commercially available automated immunoassays for the determination of Epstein-Barr virus serological status.Clin Vaccine Immunol. 2012 Jun;19(6):929-34. doi: 10.1128/CVI.00100-12. Epub 2012 Apr 25. Clin Vaccine Immunol. 2012. PMID: 22539474 Free PMC article.
-
Comparison of Elecsys and Liaison immunoassays to determine Epstein-Barr virus serological status using further diagnostic approaches to clarify discrepant results.J Med Virol. 2023 Jan;95(1):e28166. doi: 10.1002/jmv.28166. Epub 2022 Oct 1. J Med Virol. 2023. PMID: 36137986 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical